This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Tissue factor antibody-drug conjugate (ADC)
Description: HuMax-TF ADC is an antibody-drug conjugate (ADC) targeted to Tissue Factor (TF), a protein involved in tumor signaling and angiogenesis. TF is highly expressed on many solid tumors. HuMax-TF was selected from a panel of over 70 antibodies based on its ability to bind to TF, inhibit tumor signaling, engage immune effector mechanisms and inhibit tumor growth in pre-clinical experiments.
Deal Structure: In September 2010, Genmab and Seattle Genetics announced that the companies entered into an antibody-drug conjugate (ADC) research collaboration agreement. Under the agreement, Genmab has rights to utilize Seattle Genetics ADC technology with its HuMax-TF antibody targeting the Tissue Factor antigen, which is expressed on numerous types of solid tumors. Seattle Genetics received an undisclosed upfront payment and has the right to exercise a co-development option for any resulting ADC products at the end of Phase I clinical development.
Genmab is responsible for research, manufacturing, preclinical development and Phase I clinical trials of ADCs under this collaboration. Seattle Genetics will receive research support payments for any assistance provided to Genmab. If Seattle Genetics opts into an ADC product at the end of Phase I, the companies would co-develop and share all future costs and profits for the product on a 50:50 basis. If Seattle Genetics does not opt in to an ADC...See full deal structure in Biomedtracker
Partners: Seattle Genetics, Inc.
HuMax-TF ADC News
Additional information available to subscribers only: